CTRI/2020/07/026354已完成1 期
Phase I/II randomized controlled clinical trial to assess safety and efficacy of ozone therapy via rectal insufflation and minor auto haemotherapy as an adjuvant in mild to moderate Covid-19 subjects. - Nil
Bisleri Charitable Trust0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Covid 19 positive RT-PCR (nasopharyngeal swab) result
- •Adults 30 to 60 of both sex
- •Mild to Moderately severe disease (NEWS score Less than or equal to 8)
- •Patients willing to provide informed consent
排除标准
- •Requiring ICU admission and or artificial ventilation at the screening
- •Any other comorbidity which is with a critical stage at a screening
- •Any other condition by which subject proves unfit from investigator perspective
- •Chronic constipation for more than 7 days at the time of screening
- •Severe stage of disease (NEWS score more than 8)
- •Patients with G6PD deficiency
- •Pregnant and breastfeeding women
研究者
相似试验
进行中（未招募）
1 期
An open, randomized clinical phase I/II trial to investigate maximum tolerated dose, efficacy, and safety of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide compared to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses IV in patients with relapsed/refractory multiple myelomaEUCTR2008-003829-16-DEGMIHO - Gesellschaft für medizinische Innovation Hämatologie und Onkologie mbH70
招募中
1 期
Treatment of severe COVID-19 with angiotensin-(1-7)Severe Infection with Sara-CoV-2C01.925.782.600.550.200RBR-35734pAngitec
进行中（未招募）
不适用
An open, randomised clinical Phase I/IIa trial to investigate the maximum tolerated dose, efficacy, safety and pharmacokinetics of repeated three-week courses of a single dose i.v. BI 2536 on day 1 in comparison to single doses i.v. BI 2536 on days 1, 2 and 3 in patients over 60 years of age with refractory or relapsed acute myeloid leukaemia -Male or female patients older than 60 years of age with confirmed AML (except for APL) according to the WHO definition who relapsed after or are refractory to prior chemotherapy. Leukocyte count should be = 25,000 /µl (25 x 109/Liter). Patient should be not eligible for intensive treatment options. Patient should have a life expectancy = 2 months and Eastern co-operative oncology group performance score of 2 or less.MedDRA version: 8.1Level: LLTClassification code 10001941Term: AMEUCTR2006-000613-38-ATBoehringer Ingelheim Austria GmbH60
进行中（未招募）
不适用
An open, randomised clinical Phase I/IIa trial to investigate the maximum tolerated dose, efficacy, safety and pharmacokinetics of repeated three-week courses of a single dose i.v. BI 2536 on day 1 in comparison to single doses i.v. BI 2536 on days 1, 2 and 3 in patients over 60 years of age with refractory or relapsed acute myeloid leukaemiaEUCTR2006-000613-38-DEBoehringer Ingelheim Pharma GmbH & Co. KG60
进行中（未招募）
1 期
An early-stage clinical trial to evaluate the safety and effectiveness of GDC-0032 when given alongside Tamoxifen to patients with HER2 negative advanced breast cancer, who have previously received hormone treatmentHormone receptor positive metastatic breast cancerMedDRA version: 19.0Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2013-003947-51-GBKI-AV322